Безрецептурный напроксен в ревматологической практике: область применения и терапевтические преимущества

Безрецептурные нестероидные противовоспалительные препараты (НПВП) содержат относительно низкую дозу действующего вещества и предназначены для кратковременного приема (3–5 дней). Они эффективны и удобны при лечении скелетно-мышечной боли во многих клинических ситуациях в ревматологической практике. Безрецептурный напроксен в дозе 275 мг обладает доказанной анальгетической эффективностью, длительностью действия до 12–15 ч после однократного приема и благоприятным профилем безопасности. Он может с успехом применяться для терапии обострений остеоартрита, кратковременных эпизодов боли при стабильном течении аутоиммунных воспалительных ревматических заболеваний, при острой неспецифической боли в спине и в дебюте патологии околосуставных мягких тканей. Этот препарат, с учетом национальных рекомендаций по использованию НПВП, может назначаться на короткое время в качестве анальгетической терапии у пациентов с высоким риском кардиоваскулярных осложнений. Особую ценность он представляет для амбулаторной практики, поскольку пациенты могут его свободно приобрести и использовать в соответствии с принципами «ответственного самолечения».

нестероидные противовоспалительные препараты, напроксен, напроксен натрия, Тералив 275®, эффективность, безопасность, ревматические заболевания

1. Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетномышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;54(3):247-65.

2. Cao Y, Fan D, Yin Y. Pain Mechanism in Rheumatoid Arthritis: From Cytokines to Central Sensitization. Mediators Inflamm. 2020 Sep 12;2020:2076328. doi: 10.1155/2020/2076328. eCollection

3. Berenbaum F, Walker C. Osteoarthritis and inflammation: a serious disease with overlapping phenotypic patterns. Postgrad Med. 2020 May;132(4):377-84. doi: 10.1080/00325481. 2020.1730669. Epub 2020 Feb 26.

4. Lampa J. Pain without inflammation in rheumatic diseases. Best Pract Res Clin Rheumatol. 2019 Jun;33(3):101439. doi: 10.1016/j.berh.2019.101439. Epub 2019 Sep 6.

5. Lwin MN, Serhal L, Holroyd C, Edwards CJ. Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review. Rheumatol Ther. 2020 Sep;7(3):457-71. doi: 10.1007/s40744-020-00217-4. Epub 2020 Jun 13.

6. Pincus T, Castrejon I, Yazici Y, et al. Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each disease. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5): 7-17. Epub 2019 Oct 14.

7. Harth M, Nielson WR. Pain and affective distress in arthritis: relationship to immunity and inflammation. Expert Rev Clin Immunol. 2019 May;15(5):541-52. doi: 10.1080/1744666X.2019.1573675. Epub 2019 Feb 11.

8. Michaud K, Pope J, van de Laar M, et al. A Systematic Literature Review of Residual Symptoms and Unmet Need in Patients with Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2020 Jul 3. doi: 10.1002/acr.24369. Online ahead of print.

9. Vergne-Salle P, Pouplin S, Trouvin A, et al. The burden of pain in rheumatoid arthritis: Impact of disease activity and psychological factors. Eur J Pain. 2020 Aug 25. doi: 10.1002/ejp.1651. Online ahead of print.

10. Steffen А, Holstiege J, Klimke K, et al. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. Rheumatol Int. 2018 Nov;38(11): 2111-20. doi: 10.1007/s00296-018-4161-7. Epub 2018 Oct 10.

11. Charlesworth J, Fitzpatrick J, Perera NKP, Orchard J. Osteoarthritis – a systematic review of long-term safety implications for osteoarthritis of the knee. BMC Musculoskelet Disord. 2019 Apr 9;20(1):151. doi: 10.1186/s12891-019-2525-0.

12. Akazawa M, Mimura W, Togo K, et al. Patterns of drug treatment in patients with osteoarthritis and chronic low back pain in Japan: a retrospective database study. J Pain Res. 2019 May 21;12:1631-48. doi: 10.2147/JPR.S203553. eCollection 2019.

13. Zeng C, Zhang W, Doherty M, et al. Initial analgesic prescriptions for osteoarthritis in the United Kingdom, 2000-2016. Rheumatology (Oxford). 2020 Jun 28;keaa244. doi: 10.1093/rheumatology/keaa244. Online ahead of print.

14. Rane MA, Gitin A, Fiedler B, et al. Risks of Cardiovascular Disease and Beyond in Prescription of Nonsteroidal AntiInflammatory Drugs. J Cardiovasc Pharmacol Ther. 2020 Jan;25(1):3-6. doi: 10.1177/1074248419871902. Epub 2019 Aug 29.

15. Braun J, Baraliakos X, Westhoff T. Nonsteroidal anti-inflammatory drugs and cardiovascular risk – a matter of indication. Semin Arthritis Rheum. 2020 Apr;50(2):285-8. doi: 10.1016/j.semarthrit.2019.07.012.

16. Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. Gastroenterology. 2018 Feb;154(3):500-14. doi: 10.1053/j.gastro.2017.10.049. Epub 2017 Dec 6.

17. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal AntiInflammatory Drug Use in The Elderly. Aging Dis. 2018 Feb 1;9(1):143-50. doi: 10.14336/AD.2017.0306. eCollection 2018 Feb.

18. Cooper C, Chapurlat R, Al-Daghri N, et al. Safety of Oral Non-Selective NonSteroidal Anti-Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Drugs Aging. 2019 Apr;36(Suppl 1):15-24. doi: 10.1007/s40266-019-00660-1.

19. Bally M, Beauchamp ME, Abrahamowicz M, et al. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):69-77. doi: 10.1002/pds.4358. Epub 2017 Nov 24.

20. Guillemin F, Ricatte C, Barcenilla-Wong A, et al. Developing a Preliminary Definition and Domains of Flare in Knee and Hip Osteoarthritis (OA): Consensus Building of the Flare-in-OA OMERACT Group. J Rheumatol. 2019 Sep;46(9):1188-191. doi: 10.3899/jrheum.181085. Epub 2019 May 15.

21. Parry E, Ogollah R, Peat G. 'Acute flareups' in patients with, or at high risk of, knee osteoarthritis: a daily diary study with casecrossover analysis. Osteoarthritis Cartilage. 2019 Aug;27(8):1124-1128. doi: 10.1016/j.joca.2019.04.003. Epub 2019 Apr 14.

22. Thomas MJ, Yu D, Nicholls E, et al. Short-term recovery trajectories of acute flares in knee pain: a UK-Netherlands multicentre prospective cohort analysis. Arthritis Care Res (Hoboken). 2019 Oct 10;10.1002/acr. 24088. doi: 10.1002/acr.24088.

23. Каратеев АЕ. Пациент с остеоартритом вне «поля зрения» врача: как контролировать боль в суставах в рамках концепции «ответственного самолечения»? Неврология, нейропсихиатрия, психосоматика. 2019;11(Прил. 2):52-61. doi: 10.14412/2074-2711-2019-2S-52-61

24. Noone J, Blanchette CM. The value of self-medication: summary of existing evidence. J Med Econ. 2018 Feb;21(2):201-11. doi: 10.1080/13696998.2017.1390473. Epub 2017 Nov 3.

25. Ferreira ML, Zhang Y, Metcalf B, et al. The influence of weather on the risk of pain exacerbation in patients with knee osteoarthritis – a case-crossover study. Osteoarthritis Cartilage. 2016 Dec;24(12):2042-47. doi: 10.1016/j.joca.2016.07.016. Epub 2016 Aug 1.

26. Peultier L, Lion A, Chary-Valckenaere I, et al. Influence of meteorological elements on balance control and pain in patients with symptomatic knee osteoarthritis. Int J Biometeorol. 2017 May;61(5):903-10. doi: 10.1007/s00484-016-1269-x. Epub 2016 Nov 10.

27. Brutzkus JC, Shahrokhi M, Varacallo M. Naproxen. 2020 May 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. PMID: 30247840

28. Angiolillo D, Weisman S. Clinical Pharmacology and Cardiovascular Safety of Naproxen. Am J Cardiovasc Drugs. 2017 Apr; 17(2):97-107. doi: 10.1007/s40256-016-0200-5.

29. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

30. Antman E, Bennett J, Daugherty A, et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007 Mar 27;115(12):1634-42. doi: 10.1161/CIRCULATIONAHA.106. 181424. Epub 2007 Feb 26.

31. Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May; 70(5):818-22. doi: 10.1136/ard.2010.128660. Epub 2010 Sep 10.

32. https://www.nice.org.uk/advice/ktt13/resources/nonsteroidal-antiinflammatorydrugs-pdf-58757951055301

33. Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(Прил. 1):1-29.

34. Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jan 21; 2009(1):CD004234. doi: 10.1002/14651858. CD004234.pub3.

35. Smith SR, Deshpande BR, Collins JE, et al. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthritis Cartilage. 2016 Jun;24(6):962-72. doi: 10.1016/j.joca.2016.01. 135. Epub 2016 Feb 1.

36. Williams H, Ward J, Egger M, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993 Sep; 36(9):1196-206. doi: 10.1002/art.1780360904.

37. Temple AR, Benson GD, Zinsenheim JR, Schweinle JE. Multicenter, randomized, double-blind, active-controlled, parallel-group trial of the long-term (6–12 months) safety of acetaminophen in adult patients with osteoarthritis. Clin Ther. 2006 Feb;28(2):222-35. doi: 10.1016/j.clinthera.2006.02.004.

38. Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. doi: 10.1136/ard.2006.059162. Epub 2006 Dec 1.

39. Fathi M, Zare MA, Bahmani HR, Zehtabchi S. Comparison of oral oxycodone and naproxen in soft tissue injury pain control: a double-blind randomized clinical trial. Am J Emerg Med. 2015 Sep;33(9):1205-8. doi: 10.1016/j.ajem.2015.05.021. Epub 2015 May 29.

40. Plapler PG, Scheinberg MA, Ecclissato CC, et al. Double-blind, randomized, double-dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Des Devel Ther. 2016 Jun 17;10:1987-93. doi: 10.2147/DDDT.S97756. eCollection 2016.

41. Golden HE, Moskowitz RW, Minic M. Analgesic efficacy and safety of nonprescription doses of naproxen sodium compared with acetaminophen in the treatment of osteoarthritis of the knee. Am J Ther. 2004 Mar-Apr;11(2):85-94. doi: 10.1097/00045391-200403000-00002.

42. Schiff M, Minic M. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee. J Rheumatol. 2004 Jul;31(7):1373-83.

43. Lila AM, Parfenov VA, Cattry E, ParedesDiaz A. Pharmacokinetic linearity of naproxen and efficacy of naproxen sodium at various doses. Int J Clin Pharmacol Ther. 2020 Jun; 58(6):316-31. doi: 10.5414/CP203696.

44. Cooper S, Desjardins P, Brain P, et al. Longer analgesic effect with naproxen sodium than ibuprofen in post-surgical dental pain: a randomized, double-blind, placebo-controlled, single-dose trial. Curr Med Res Opin. 2019 Dec;35(12):2149-58. doi: 10.1080/03007995.2019.1655257. Epub 2019 Aug 27.

45. Bansal V, Dex T, Proskin H, Garreffa S. A look at the safety profile of over-the-counter naproxen sodium: a meta-analysis. J Clin Pharmacol. 2001 Feb;41(2):127-38. doi: 10.1177/00912700122009935.

46. McGettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011 Sep;8(9):e1001098. doi: 10.1371/journal.pmed.1001098. Epub 2011 Sep 27.